Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Belite Bio, Inc - American Depositary Shares
(NQ:
BLTE
)
38.37
-1.56 (-3.91%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Mar 28, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
35,328
Open
39.70
Bid (Size)
37.91 (3)
Ask (Size)
38.38 (4)
Prev. Close
39.93
Today's Range
37.02 - 39.98
52wk Range
11.00 - 48.60
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Belite Bio Announces PMDA Submission of Tinlarebant for Stargardt Disease Clinical Trial in Japan
March 22, 2024
From
Belite Bio, Inc
Via
GlobeNewswire
Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website
March 11, 2024
From
Belite Bio, Inc
Via
GlobeNewswire
Performance
YTD
-10.27%
-10.27%
1 Month
-17.98%
-17.98%
3 Month
-16.62%
-16.62%
6 Month
+20.32%
+20.32%
1 Year
+32.31%
+32.31%
More News
Read More
Belite Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
March 11, 2024
From
Belite Bio, Inc
Via
GlobeNewswire
Expert Ratings for Belite Bio
December 14, 2023
Via
Benzinga
Expert Ratings for Belite Bio
August 10, 2023
Via
Benzinga
The Latest Analyst Ratings for Belite Bio
July 25, 2023
Via
Benzinga
Belite Bio to Host Webcast on March 12, 2024, to Discuss Fourth Quarter and Full Year 2024 Financial Results
March 06, 2024
From
Belite Bio, Inc
Via
GlobeNewswire
Belite Bio to Participate in the Leerink Partners Global Biopharma Conference
March 04, 2024
From
Belite Bio, Inc
Via
GlobeNewswire
Belite Bio to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
February 07, 2024
From
Belite Bio, Inc
Via
GlobeNewswire
Belite Bio to Participate in the Benchmark Company’s Upcoming Discovery One-on-One Investor Conference
November 30, 2023
From
Belite Bio, Inc
Via
GlobeNewswire
Belite Bio to Participate in the BTIG Ophthalmology Day
November 20, 2023
From
Belite Bio, Inc
Via
GlobeNewswire
Belite Bio Reports Third Quarter 2023 Operational Highlights and Financial Results
November 13, 2023
From
Belite Bio, Inc
Via
GlobeNewswire
Deutsche Bank ADR Investor Conference: Presentations Now Available for Online Viewing
November 10, 2023
From
Virtual Investor Conferences
Via
GlobeNewswire
Belite Bio to Host Webcast on November 14, 2023, to Discuss Third Quarter 2023 Financial Results
November 07, 2023
From
Belite Bio, Inc
Via
GlobeNewswire
Belite Bio, Inc. to present at the Deutsche Bank ADR Virtual Investor Conference on 8 November 2023
November 06, 2023
From
Virtual Investor Conferences
Via
GlobeNewswire
Belite Bio Presents Results from a 24-month, Phase 2 Study of Tinlarebant in Childhood-onset Stargardt Disease at the AAO Annual Meeting
November 06, 2023
From
Belite Bio, Inc
Via
GlobeNewswire
International companies to host live webcasts at Deutsche Bank’s Depositary Receipts
November 01, 2023
From
Virtual Investor Conferences
Via
GlobeNewswire
Belite Bio Announces Presentation at the American Academy of Ophthalmology 2023 Annual Meeting
October 27, 2023
From
Belite Bio, Inc
Via
GlobeNewswire
Why 22nd Century Group Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Monday's Mid-Day Session
August 14, 2023
Via
Benzinga
Belite Bio Reports Second Quarter 2023 Operational Highlights and Financial Results
August 08, 2023
From
Belite Bio, Inc
Via
GlobeNewswire
Belite Bio to Host Webcast on August 9, 2023 to Discuss Second Quarter 2023 Financial Results
August 04, 2023
From
Belite Bio, Inc
Via
GlobeNewswire
Belite Bio Doses First Subject in Pivotal Phase 3 PHOENIX Trial Evaluating Oral Tinlarebant for GA
July 27, 2023
From
Belite Bio, Inc
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For July 28, 2023
July 28, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 26, 2023
July 26, 2023
Via
Benzinga
Belite Bio Completes Enrollment in Pivotal Global Phase 3 DRAGON Trial Evaluating Oral Tinlarebant for Stargardt Disease
July 24, 2023
From
Belite Bio, Inc
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.